Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value

$18.75+0.61 (+3.36%)

Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –

Acadia Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

For fiscal 2011 it was $32.00K, down 59.0% from the year before.

Period	Period end	Value	Change
FY2011	Dec 31, 2011	$32.00K	-59.0%
FY2010	Dec 31, 2010	$78.00K	–

Parsed from the XBRL in Acadia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACAD.

Revenue growth14.8% · median 19.8%

Gross margin90.5% · median 84.5%

Operating margin10.2% · median 7.0%

Net margin30.1% · median -2.6%

Advertisement
300 × 250

See a number that looks wrong?